阿司匹林抵抗的产生机制与防治策略
4 展望
对于AR,还存在很多未知因素,其复杂性和群体特征性是并存的,需进一步深入研究。在研究AR及临床防治AR时,应在考虑其复杂性的基础上,兼顾群体差别性,区别地辨证地对待这种现象,针对不同的群体制定不同的研究方案,为不同的个体制定更有效的治疗策略,使个体化治疗得到更高层次的体现。比如,我们可根据挟杂危险因素的不同来划分不同的群体,通过研究这些不同群体中AR产生的机理,相应地揭示其可能的群体特征。目前,关于AR的研究还不够全面,不够系统,也存在很多争议,结合中医中药,针对不同的群体进行AR的产生机理及防治方面的研究是一条值得探索之路。
【参考文献】
1 Sztriha LK, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005; (229-230): 163-169.
2 Weber ZZ, Zimmermann KC, Meyer-Kirchrath J, et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999; 353: 900.
3 Weber AA, Przytulski B, Schumacher M, et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Br J Haematol. 2002; 117(2): 424-426.
4 Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99: 7634-7639.
5 Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142(3): 157-164.
6 Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165(9): 978-984.
7 Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, et al. Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Thromb Res. 2003; 111(4-5): 259-265.
8 Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345(25): 1809-1817.
9 Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther. 2005; 27(2): 185-191.
10 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004; 4(3): 151-158.
11 Helgason CM, Tortorice KL, Winkler SR, et al. Aspi-rin response and failure in cerebral infarction. Stroke. 1993; 24(3): 345-350.
12 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86.
13 Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin inhealthy volunteers. Stroke. 2006; 37(8): 2153-2158
14 Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107(1-2): 45-49.
15 Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2002; 108(2-3): 115-119.
16 Mattiasson I, Lethagen S, Hillarp A. Increased sensi-tivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? Int Angiol. 2003; 22(3): 239-242.
17 Payne DA, Jones CI, Hayes PD, et al. Platelet inhibi-tion by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost. 2004; 92(1): 89-96.
18 Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital. Am J Cardi-ol. 2006; 98(5): 577-579.
19 Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol. 2003; 42(6): 1115-1119.
20 Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88(3): 230-235.
21 Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1- adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens. 2001; 15(3): 203-207.
- 上一篇:中药的使用会威胁生物多样性吗?
- 下一篇:中药抗组织损伤与白细胞黏附